PN vs PDRN
This page places verifiable specifications side by side. It does not rank materials, score them, or recommend one over another.
Comparison
What is the difference between polynucleotide and polydeoxyribonucleotide?
Both are DNA-derived biopolymers from the same family, and the review literature separates them on one variable: fragment length. PN sits at the longer end of the molecular weight range and reviews attribute extracellular matrix remodelling to it; PDRN sits at the shorter end and its reported activity runs through the adenosine A2A receptor. In practice the two names are used interchangeably, which means a claim carried between them has crossed the exact variable the literature says distinguishes them.
| Aspect | PN (Polynucleotide) | PDRN (Polydeoxyribonucleotide) | Basis |
|---|---|---|---|
| Family | DNA-derived biopolymer | DNA-derived biopolymer | — |
| Variable the literature separates them on | Longer fragments, higher molecular weight | Shorter fragments, lower molecular weight | — |
| Molecular weight range described for the family | Reviews place the family at roughly 50-1500 kDa, with PN toward the longer end | Reviews place the family at roughly 50-1500 kDa, with PDRN toward the shorter end | — |
| Primary activity attributed in reviews | Extracellular matrix remodelling | Adenosine A2A receptor engagement, with salvage-pathway activity | — |
| Mechanism page on this site | Not separated — the A2A page covers the family and notes the split | Adenosine A2A receptor pathway | — |
| Highest-tier evidence cited on this site | Randomised comparison against hyaluronic acid (PMID 32248707) | Systematic review of wound healing and tissue regeneration (PMID 32757710) | — |
| Regulatory identity — all six markets | Not established from public sources | Not established from public sources | — |
One variable, two names
Reviews in this field exist partly to fix a terminology problem: the same class of material is sold under two names that the literature assigns different primary activity to. The separating variable is fragment length, and it is not a detail — it is what the attributed mechanisms hang on. A page that treats the two as synonyms has already discarded the distinction before making any claim.
What this means when reading a study
Before carrying a result from a paper to a product, establish which material the paper used and where it sat in the molecular weight range. Papers do not always report this, and when they do not, the finding cannot be assigned to one side of this comparison with confidence.
Both remain regulatorily unresolved here
Neither material could be given a single classification in any of the six markets tracked on this site. That is unusual — most entries in this atlas resolve in at least Korea and the European Union. The reason is the same one this page is about: these agents are marketed through more than one regulatory lane, and which lane applies depends on presentation and claim rather than on the molecule.
Limitations & open questions
No study cited here places the two in one protocol, and the randomised trial listed on the PN side used a hyaluronic acid comparator rather than PDRN. Because product labelling in this field does not consistently maintain the distinction, some published work attributed to one name may have used material that the review literature would classify as the other. Searches in this area return several retracted papers among the top results, including a phase III randomised trial, so record status should be confirmed before any citation in this field is relied on.